This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Oxsoralen-Ultra

Cipher Pharmaceuticals Inc.

Drug Names(s): methoxsalen, 8-methoxypsoralen

Description: Oxsoralen-Ultra contains Methoxsalen, a naturally occurring photoactive substance found in the seeds of the Ammi majus (Umbelliferae) plant and in the roots of Heracleum Candicans. It belongs to a group of compounds known as psoralens, or furocoumarins.

Oxsoralen-Ultra is given in combination with UV light. The combination treatment regimen of psoralen (P) and ultraviolet radiation of 320-400 nm wavelength commonly referred to as UVA is known by the acronym, PUVA. Skin reactivity to UVA (320-400 nm) radiation is markedly enhanced by the ingestion of methoxsalen.

Methoxsalen acts as a photosensitizer. Administration of the drug and subsequent exposure to UVA can lead to cell injury. Orally administered methoxsalen reaches the skin via the blood and UVA penetrates well into the skin. If sufficient cell injury occurs in the skin, an inflammatory reaction occurs. The most obvious manifestation of this reaction is delayed erythema, which may not begin for several hours and peaks at 48-72 hours. The inflammation is followed, over several days to weeks, by repair which is manifested by increased melanization of the epidermis and thickening of the stratum corneum. The mechanisms of therapy are not known. In the treatment of psoriasis, the mechanism is most often assumed to be DNA photodamage and resulting decrease in cell proliferation but other vascular, leukocyte, or cell regulatory mechanisms may also be playing some role.

Deal Structure: JSJ and Valeant
In February 2007, JSJ Pharmaceuticals announced a multi-year agreement under which it has assumed from Valeant Pharmaceuticals International the sales, marketing, and educational responsibilities for Oxsoralen-Ultra.

In 2011, JSJ Pharmaceuticals changed its name to Innocutis Holdings.

Cipher and Innocutis
In April 2015, Cipher announced that it has acquired INNOCUTIS Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash.

Partners: Valeant Pharmaceuticals International, Inc.


Oxsoralen-Ultra News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug